IS2075A7 - Aðferð til framleiðslu á 1, 2, 4, - triazole nucleosides - Google Patents

Aðferð til framleiðslu á 1, 2, 4, - triazole nucleosides

Info

Publication number
IS2075A7
IS2075A7 IS2075A IS2075A IS2075A7 IS 2075 A7 IS2075 A7 IS 2075A7 IS 2075 A IS2075 A IS 2075A IS 2075 A IS2075 A IS 2075A IS 2075 A7 IS2075 A7 IS 2075A7
Authority
IS
Iceland
Prior art keywords
production
triazole nucleosides
nucleosides
triazole
Prior art date
Application number
IS2075A
Other languages
English (en)
Other versions
IS913B6 (is
Inventor
Theodore Witkowski Joseph
Kenith Robins Roland
Original Assignee
International Chemical & Nuclear Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Chemical & Nuclear Corporation filed Critical International Chemical & Nuclear Corporation
Publication of IS2075A7 publication Critical patent/IS2075A7/is
Publication of IS913B6 publication Critical patent/IS913B6/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS2075A 1971-06-01 1972-05-15 Aðferð til framleiðslu á 1, 2, 4, - triazole nucleosides IS913B6 (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14901771A 1971-06-01 1971-06-01
US24025272A 1972-03-31 1972-03-31

Publications (2)

Publication Number Publication Date
IS2075A7 true IS2075A7 (is) 1973-01-02
IS913B6 IS913B6 (is) 1975-09-15

Family

ID=26846393

Family Applications (1)

Application Number Title Priority Date Filing Date
IS2075A IS913B6 (is) 1971-06-01 1972-05-15 Aðferð til framleiðslu á 1, 2, 4, - triazole nucleosides

Country Status (28)

Country Link
US (1) US3798209A (is)
JP (5) JPS5527076B1 (is)
AR (1) AR199463A1 (is)
AU (1) AU461900B2 (is)
BE (1) BE784195A (is)
BG (1) BG22827A3 (is)
CA (1) CA997756A (is)
CH (1) CH614452A5 (is)
DD (1) DD99791A5 (is)
DE (1) DE2220246A1 (is)
DK (2) DK143069C (is)
EG (1) EG11406A (is)
ES (1) ES403142A1 (is)
FR (1) FR2140126B1 (is)
GB (1) GB1353565A (is)
HK (1) HK23876A (is)
HU (1) HU167614B (is)
IE (1) IE36478B1 (is)
IL (1) IL39416A (is)
IN (1) IN142290B (is)
IS (1) IS913B6 (is)
LU (1) LU65446A1 (is)
MC (1) MC921A1 (is)
MY (1) MY7600203A (is)
NL (1) NL7207156A (is)
NO (1) NO138805C (is)
RO (1) RO62435A (is)
SE (3) SE405604B (is)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
DE2401449A1 (de) * 1973-01-16 1974-07-25 Voorhees Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen
US3888843A (en) * 1973-06-12 1975-06-10 Toyo Jozo Kk 4-carbamoyl-1-' -d-ribofuranosylimidazolium-5-olate
GB1482736A (en) * 1974-03-18 1977-08-10 Icn Pharmaceuticals 1-(beta-d-ribofuranosyl)-1,2,4-triazole acid derivatives
AR207138A1 (es) * 1974-03-18 1976-09-15 Icn Pharmaceuticals Metodo para la obtencion de 1,2,4-triazoles n-substituidos y sus sales de adicion
US3960836A (en) * 1974-07-22 1976-06-01 Eli Lilly And Company Acylated derivatives of pyrazofurin and process for their preparation
US4007198A (en) * 1975-05-01 1977-02-08 American Cyanamid Company Substituted 1,2,4-triazole carboxamide
US4138547A (en) * 1977-12-22 1979-02-06 Icn Pharmaceuticals, Inc. Process for preparing 1,2,4-triazole nucleosides
JPS57146593A (en) * 1981-03-09 1982-09-10 Ajinomoto Co Inc Preparation of ribofuranosyltriazole derivative
US4451648A (en) * 1981-08-19 1984-05-29 The United States Of America As Represented By The Department Of Health And Human Services Process for the production of 2-β-D-ribofuranosylthiazole-4-carboxamide
US4531001A (en) * 1982-03-23 1985-07-23 Brigham Young University 2-β-D-ribofuranosylselenazole-4-carboxamide compounds
US4446315A (en) * 1982-09-24 1984-05-01 The United States Of America As Represented By The Department Of Health And Human Services Adenosine 5'-triphosphate-4-carboxamide-ribofuranosylthiazole
JPS5964648U (ja) * 1982-10-22 1984-04-28 阿波野　政晴 日覆用骨格
BE902199A (fr) * 1984-10-29 1985-07-31 Vira Tek Inc Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1, 2,4-triazole-3-carboxamide.
NZ213370A (en) * 1985-01-16 1989-03-29 Vira Tek Inc Method of treating viral infections of selected trees and field crops using ribavirin (1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide) or the 2,3,5-triacetyl or 5'-butyryl derivative thereof
DE3606634A1 (de) * 1986-02-28 1987-09-03 Mack Chem Pharm Isohexid-nucleoside, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU5668886A (en) * 1986-03-27 1987-10-20 Harry Edward Gruber A method of increasing adenosine excretion
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
US5438131A (en) * 1992-09-16 1995-08-01 Bergstrom; Donald E. 3-nitropyrrole nucleoside
CA2384326A1 (en) * 1999-12-23 2001-06-28 Johnson Lau Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
US7638496B2 (en) * 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (en) * 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
US6815542B2 (en) * 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
AU2001220806A1 (en) * 2000-08-22 2002-03-04 Ribapharm Inc. Improved specificity in treatment of diseases
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
US20040014696A1 (en) * 2000-12-07 2004-01-22 Johnson Lau Specificity in treatment of diseases
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
DE60101056T2 (de) * 2001-07-30 2004-05-19 Clariant Life Science Molecules (Italia) S.P.A., Origgio Verfahren zur Herstellung von Ribavirin
EP1435974A4 (en) * 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
CN1585631A (zh) * 2001-11-02 2005-02-23 桑多斯公司 制备快速溶解的高填量利巴韦林组合物的方法
KR100411398B1 (ko) 2001-12-06 2003-12-18 주식회사유한양행 베타-디-리보푸라노즈 유도체의 제조방법
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US20040067877A1 (en) * 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
US7538094B2 (en) * 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
AU2003300901A1 (en) * 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
NZ540913A (en) * 2002-12-23 2008-02-29 Idenix Cayman Ltd Process for the production of 3'-nucleoside prodrugs
WO2004084796A2 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US20050075309A1 (en) 2003-07-25 2005-04-07 Richard Storer Purine nucleoside analogues for treating Flaviviridae including hepatitis C
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
CA2571675A1 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US8492539B2 (en) * 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
MX2008001166A (es) * 2005-07-25 2008-03-18 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
AU2006301966A1 (en) * 2005-10-11 2007-04-19 Array Biopharma, Inc. Compounds and methods for inhibiting hepatitis C viral replication
ES2422290T3 (es) * 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
EP2007789B1 (en) 2006-04-11 2015-05-20 Novartis AG Spirocyclic HCV/HIV inhibitors and their uses
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2009028575A1 (ja) 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固第vii因子プロモーターの活性化剤及びその利用
WO2009028573A1 (ja) 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固障害におけるリバビリンの利用
US20090082414A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched viramidine
US8466276B2 (en) 2008-02-22 2013-06-18 Nektar Therapeutics Oligomer conjugates of heteropentacyclic nucleosides
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
EA201071034A1 (ru) * 2008-04-15 2011-06-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликаций вируса гепатита с
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2358736A1 (en) * 2008-10-15 2011-08-24 Intermune, Inc. Therapeutic antiviral peptides
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
AU2009329872B2 (en) * 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ593649A (en) * 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
TWI583692B (zh) * 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
IN2012DN02693A (is) * 2009-09-28 2015-09-04 Intermune Inc
TW201116540A (en) * 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
WO2011076923A1 (en) 2009-12-23 2011-06-30 Institut National De La Sante Et De La Recherche Medicale Inhibitor for inosine monophosphate (imp) dehydrogenase and/or viral rna polymerase for treatment of hepatitis e
PE20130244A1 (es) * 2010-01-25 2013-03-10 Enanta Pharm Inc Inhibidores del virus de la hepatitis c
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
JP5909495B2 (ja) 2010-10-08 2016-04-26 ノバルティス アーゲー スルファミドｎｓ３阻害剤のビタミンｅ製剤
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US20130273005A1 (en) 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv
CA2752008A1 (en) 2011-09-13 2013-03-13 Universite De Montreal Combination therapy using ribavirin as elf4e inhibitor
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2912047B1 (en) 2012-10-29 2016-08-24 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
US20170151272A1 (en) 2014-06-23 2017-06-01 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A novel pharmaceutical composition of sofosbuvir and ribavirin
WO2015197535A1 (en) 2014-06-23 2015-12-30 Sanovel Ilac Sanayi Ve Ticaret A.S. Modified release pharmaceutical compositions of sofosbuvir and ribavirin
US20170112867A1 (en) 2014-06-23 2017-04-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of sofosbuvir and ribavirin
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
TW201817714A (zh) 2016-08-30 2018-05-16 英商葛蘭素史密斯克藍智慧財產權有限公司 抑制3c及3cl蛋白酶之化合物及其使用方法
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
CN110713464B (zh) * 2019-10-31 2023-03-31 重庆大学 一种芳基1,2,4-三氮唑核苷化合物及其制备方法和应用
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN116621899B (zh) * 2023-05-18 2026-02-06 中国人民解放军军事科学院军事医学研究院 非天然核苷类似物及其用途

Also Published As

Publication number Publication date
SE7801926L (sv) 1978-02-20
DD99791A5 (is) 1973-08-20
NO138805B (no) 1978-08-07
IE36478B1 (en) 1976-11-10
AR199463A1 (es) 1974-09-09
RO62435A (fr) 1978-03-15
CH614452A5 (en) 1979-11-30
EG11406A (en) 1981-06-30
NO138805C (no) 1978-11-15
JPS5387356A (en) 1978-08-01
DK509876A (da) 1976-11-12
JPS5395974A (en) 1978-08-22
FR2140126B1 (is) 1976-04-16
IS913B6 (is) 1975-09-15
ES403142A1 (es) 1975-05-01
JPS53108973A (en) 1978-09-22
LU65446A1 (is) 1972-10-05
HK23876A (en) 1976-04-30
CA997756A (en) 1976-09-28
BE784195A (fr) 1972-11-30
DE2220246A1 (de) 1972-12-14
IL39416A (en) 1975-07-28
GB1353565A (en) 1974-05-22
MY7600203A (en) 1976-12-31
IN142290B (is) 1977-06-18
IE36478L (en) 1972-12-01
JPS5519239B2 (is) 1980-05-24
SE405604B (sv) 1978-12-18
US3798209A (en) 1974-03-19
JPS5527076B1 (is) 1980-07-17
JPS53124271A (en) 1978-10-30
FR2140126A1 (is) 1973-01-12
SE7801925L (sv) 1978-02-20
MC921A1 (fr) 1973-01-25
DK143069B (da) 1981-03-23
AU461900B2 (en) 1975-06-12
HU167614B (is) 1975-11-28
JPS5519238B2 (is) 1980-05-24
AU4215772A (en) 1973-12-20
NL7207156A (is) 1972-12-05
DK143069C (da) 1981-11-02
IL39416A0 (en) 1972-07-26
BG22827A3 (bg) 1977-04-20

Similar Documents

Publication Publication Date Title
IS913B6 (is) Aðferð til framleiðslu á 1, 2, 4, - triazole nucleosides
BG21599A3 (bg) Метод за получаване на 1,2,3-трихлорпропен
BG19374A3 (bg) Метод за получаване на несиметрични 1,4- дехидропиридини
BG18872A3 (bg) Метод за получаване на 4-амино-1,2,4-триазин-5-они
BG20792A3 (bg) Метод за получаване на /2/ фурил - метил/ 6,7 бензоморфани
SU474150A3 (ru) Способ получени производных окса-1-диаза-3,8-спиро-(4,5)-декана
BG20336A3 (bg) Метод за получаване на 3-карбомоил-2.4.6- трийдефинил-алкилетери
DK139264B (da) Fremgangsmåde til fremstilling af olefiner.
BG20410A3 (bg) Метод за получаване на 3,4-дихидро-2н- изохинолин-1-они
AR200117A1 (es) Procedimiento para la produccion de pirazolo (3,4-b) piridina
BE788444A (fr) Procede de production de 2,5-dimethyl-2,4-hexadiene
BG20108A3 (bg) Метод за получаване на тиазоло (5,4-д)- пирамидини
FI56176B (fi) Foerfarande foer framstaellning av 2,4-diamino-5-bensylpyrimidiner
DK132221B (da) Fremgangsmåde til fremstilling af 2,4-diamino-5-benzylpyrimider.
DK130308B (da) Fremgangsmåde til fremstilling af 13β-alkylgona-4,9,11-triener.
CH552620A (fr) Procede de preparation de nouvelles quinoleines substittuees.
SU474147A3 (ru) Способ получени 1,2-дигидро-2оксо-4-диалкиламино-пиримидо(4,5- )-хиноксалин-5,10-двуокисей
DK131189B (da) Analogifremgangsmåde til fremstilling af 16-hydroxylerede 17alfa-ethynyl-17beta-hydroxy-13beta-alkylgona-4,9,11-trien-3-oner.
RO67383A (ro) Procedeu pentru prepararea unor 2,4-diamino-5-benzilpirimidine
SU444357A3 (ru) Способ получения 1,1-дигалоид3-арилпропена-1
SU443856A1 (ru) Способ получени 2,3-дигидробензодиазепинов
DK131185B (da) Fremgangsmåde til fremstilling af bis-chromoner.
BG20776A3 (bg) Метод за получаване на 1,2,3-трихлорпропен
SU430554A3 (ru) Способ получения производных 2,3-бензоксазепина
IS1998A7 (is) Endurbætt aðferð til framleiðslu á 2,3- Dihydro- lh-Pyrido- [2,3-b] [1,4]- Thiazin -2-Ones